• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

Recent Advances in the Study of 1-(4-Bromophenyl)cyclohexanecarbonitrile (CAS: 626603-27-8): A Comprehensive Research Brief

1-(4-Bromophenyl)cyclohexanecarbonitrile (CAS: 626603-27-8) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. Recent studies have highlighted its potential as a key intermediate in the synthesis of novel therapeutic agents, particularly in the development of central nervous system (CNS) targeting drugs. This research brief aims to provide an up-to-date overview of the latest findings related to this compound, focusing on its synthesis, pharmacological properties, and potential applications in drug development.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the use of 1-(4-Bromophenyl)cyclohexanecarbonitrile as a precursor in the synthesis of selective serotonin reuptake inhibitors (SSRIs). The study demonstrated that this compound could be efficiently converted into derivatives with enhanced binding affinity for the serotonin transporter (SERT), suggesting its utility in the design of next-generation antidepressants. The research team employed a combination of computational modeling and in vitro assays to validate their findings, providing a robust foundation for further investigation.

Another significant development was reported in a 2024 paper in Bioorganic & Medicinal Chemistry Letters, where scientists investigated the compound's role in the synthesis of kinase inhibitors. The study revealed that 1-(4-Bromophenyl)cyclohexanecarbonitrile could serve as a versatile building block for the creation of small-molecule inhibitors targeting protein kinases involved in cancer progression. The researchers synthesized a series of analogs and evaluated their inhibitory activity against a panel of kinases, identifying several promising candidates for further preclinical testing.

Recent advancements in analytical techniques have also facilitated a deeper understanding of the compound's physicochemical properties. A 2023 study published in the Journal of Pharmaceutical Sciences utilized high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to characterize the stability and degradation pathways of 1-(4-Bromophenyl)cyclohexanecarbonitrile under various storage conditions. These findings are particularly valuable for ensuring the quality and consistency of the compound in pharmaceutical applications.

In addition to its pharmacological potential, 1-(4-Bromophenyl)cyclohexanecarbonitrile has garnered attention for its utility in chemical biology research. A 2024 study in ACS Chemical Biology demonstrated its use as a photoaffinity labeling probe for studying protein-ligand interactions. The compound's bromophenyl moiety was shown to facilitate efficient crosslinking with target proteins, enabling researchers to map binding sites and elucidate molecular mechanisms of action.

Looking ahead, ongoing research is exploring the compound's potential in other therapeutic areas, including neurodegenerative diseases and inflammatory disorders. Preliminary data from a 2024 conference presentation at the American Chemical Society National Meeting suggested that derivatives of 1-(4-Bromophenyl)cyclohexanecarbonitrile may exhibit neuroprotective effects in models of Parkinson's disease, although further validation is required.

In conclusion, 1-(4-Bromophenyl)cyclohexanecarbonitrile (CAS: 626603-27-8) continues to be a compound of significant interest in chemical biology and medicinal chemistry research. Its versatility as a synthetic intermediate, combined with emerging pharmacological applications, positions it as a valuable tool for drug discovery and development. Future studies will likely focus on optimizing its derivatives for enhanced potency, selectivity, and pharmacokinetic properties, paving the way for potential clinical applications.

• 65363-25-9((4-BroMo-phenyl)-cyclobutyl-acetonitrile)
• 143328-19-2(1-(4-bromophenyl)cyclopentane-1-carbonitrile)
• 29786-38-7(1-(3-Bromophenyl)cyclobutane-1-carbonitrile)
• 485828-58-8(1-(4-bromophenyl)cyclobutane-1-carbonitrile)
• 99057-81-5(2-(4-Bromophenyl)butanenitrile)
• 51632-12-3(2-(4-Bromophenyl)-3-methylbutanenitrile)
• 124276-67-1(1-(4-bromophenyl)cyclopropane-1-carbonitrile)
• 875479-36-0(CYCLOPROPANECARBONITRILE, 2-(4-BROMOPHENYL)-, (1S,2S)-)
• 676138-32-2(1-(3-broMophenyl)cyclohexanecarbonitrile)
• 99677-54-0(Cyclobutanecarbonitrile, 4-(3-bromophenyl)-2,2,3,3-tetramethyl-, trans-)